Iovance Biotherapeutics (IOVA) Profit After Tax (2010 - 2026)
Iovance Biotherapeutics (IOVA) posted quarterly Profit After Tax of -$79.0 million for Q1 2026, up 31.95% year-over-year from -$59.9 million in Q1 2025, and down 9.97% quarter-over-quarter from -$71.9 million in Q4 2025.
Iovance Biotherapeutics (IOVA) Profit After Tax (2010 - 2026) Analysis & Trends
Iovance Biotherapeutics (IOVA) has reported Profit After Tax for 17 consecutive years, with -$79.0 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Profit After Tax rose 31.95% year-over-year to -$79.0 million; the TTM figure through Mar 2026 stood at -$353.8 million (up 5.74% YoY), while the FY2025 annual figure was -$391.0 million, down 5.05% from the prior year.
- Profit After Tax declined to -$79.0 million in Q1 2026 per IOVA's latest filing, from -$71.9 million in the prior quarter.
- Across five years, Profit After Tax topped out at -$71.9 million in Q4 2025 and bottomed at -$116.4 million in Q4 2023.
- Historically, Profit After Tax has averaged -$98.9 million across 5 years, with a median of -$99.6 million in 2022.
- Annual changes were most pronounced in 2022 — Profit After Tax retreated 22.12% — and 2024, when it soared 32.5%.
- Iovance Biotherapeutics' Profit After Tax stood at -$105.3 million in 2022, then dropped by 10.5% to -$116.4 million in 2023, then jumped by 32.5% to -$78.6 million in 2024, then advanced by 8.5% to -$71.9 million in 2025, then dropped by 9.97% to -$79.0 million in 2026.
- Business Quant data shows IOVA's Profit After Tax at -$79.0 million in Q1 2026, -$71.9 million in Q4 2025, and -$91.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 472.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 237.01 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -3,087.27 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 164.49 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -16.62 Mn |
| 10 | Iovance Biotherapeutics | 3.16 Bn | 2.86 Bn | 55.72 Mn | -47.32 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -47.32 Mn |
| Mar 31, 2026 | -79.05 Mn |
| Dec 31, 2025 | -71.88 Mn |
| Sep 30, 2025 | -91.25 Mn |
| Jun 30, 2025 | -111.66 Mn |
| Mar 31, 2025 | -116.16 Mn |
| Dec 31, 2024 | -78.56 Mn |
| Sep 30, 2024 | -83.54 Mn |
| Jun 30, 2024 | -97.10 Mn |
| Mar 31, 2024 | -112.98 Mn |
| Dec 31, 2023 | -116.38 Mn |
| Sep 30, 2023 | -113.76 Mn |
| Jun 30, 2023 | -106.53 Mn |
| Mar 31, 2023 | -107.37 Mn |
| Dec 31, 2022 | -105.32 Mn |
| Sep 30, 2022 | -99.62 Mn |
| Jun 30, 2022 | -99.35 Mn |
| Mar 31, 2022 | -91.61 Mn |
| Dec 31, 2021 | -99.33 Mn |
| Sep 30, 2021 | -86.12 Mn |